Novo Nordisk A/S Q2 Earnings Call Highlights
· finance.yahoo.com
Novo Nordisk A/S (NYSE:NVO) reported second-quarter adjusted sales growth of 7% at constant exchange rates, supported by GLP-1 volume growth across its obesity and diabetes franchises, while lower realized prices and manufacturing-related costs weighed on margins. Chief Executive Officer Mike Doust
Millar said the product has captured about 90% of the U.S. oral obesity-medication market despite competition entering in early April. Roughly 80% of patients u...